Previous studies show that combining Bcl‐2 family inhibitors such as ABT‐737 with gemcitabine enhances apoptosis in pancreatic cancer cells, overcoming drug resistance mechanisms.33 This evidence concerns the gene BCL2 and pancreatic neoplasm.